Evidence map›Paper›PMID 26855561›Full record

Trial reportDrug design, development and therapy2016

Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers.

Yi-Fan Zhang, Xiao-Jian Dai, Yong Yang, Xiao-Yan Chen, Ting Wang, Yun-Biao Tang, Cheng-Yuan Tsai, Li-Wen Chang, Yu-Ting Chang, Da-Fang Zhong

Open access · goldAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yi-Fan ZhangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Xiao-Jian DaiState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Yong YangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Xiao-Yan ChenState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Ting WangDepartment of Pharmacy, The First Hospital Affiliated to Lanzhou University, Lanzhou, People's Republic of China.
Yun-Biao TangDepartment of Pharmacy, The General Hospital of Shenyang Military Region, Shenyang, People's Republic of China.
Cheng-Yuan TsaiTaiGen Biotechnology Co., Ltd., Taipei, Taiwan.
Li-Wen ChangTaiGen Biotechnology Co., Ltd., Taipei, Taiwan.
Yu-Ting ChangTaiGen Biotechnology Co., Ltd., Taipei, Taiwan.
Da-Fang ZhongState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Shanghai Institute of Materia Medica · CNChinese Academy of Sciences · CNFirst Hospital of Lanzhou University · CNGeneral Hospital of Shenyang Military Region · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in humans.

methodsTwo independent, open-label, randomized, crossover studies were conducted in 24 (12 per study) healthy Chinese volunteers. In Study 1, each volunteer received a single oral dose of 500 mg of nemonoxacin alone or with 1.5 g of probenecid divided into three doses within 25 hours. In Study 2, each volunteer received a single oral dose of 500 mg of nemonoxacin alone or with multiple doses of cimetidine (400 mg thrice daily for 7 days). The plasma and urine nemonoxacin concentrations were determined using validated liquid chromatography-tandem mass spectrometry methods.

resultsCoadministration of nemonoxacin with probenecid reduced the renal clearance (CLr) of nemonoxacin by 22.6%, and increased the area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) by 26.2%. Coadministration of nemonoxacin with cimetidine reduced the CLr of nemonoxacin by 13.3% and increased AUC0-∞ by 9.4%. Coadministration of nemonoxacin with probenecid or cimetidine did not significantly affect the maximum concentration of nemonoxacin or the percentage of the administered dose recovered in the urine.

conclusionAlthough probenecid reduced the CLr and increased the plasma exposure of nemonoxacin, these effects are unlikely to be clinically meaningful at therapeutic doses. Cimetidine had weaker, clinically meaningless effects on the pharmacokinetics of nemonoxacin.

Indexed as

Administration, OralAdultAnti-Bacterial AgentsArea Under CurveAsian PeopleChromatography, LiquidCimetidineCross-Over StudiesDrug InteractionsFemaleHumansMaleProbenecidQuinolonesTandem Mass SpectrometryYoung AdultAnti-Bacterial AgentsCimetidinenemonoxacinProbenecidQuinolonescimetidineclinical pharmacokineticsdrug–drug interactionnemonoxacinprobenecid

Identifiers

PMID26855561
PMCPMC4725632
OpenAlexW2257553298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.